Lv7
3720 积分 2022-04-01 加入
EPR26-165: Risk Factors for Infection in Chronic Lymphocytic Leukemia: Insights From a Real-World Cohort Treated With Bruton Tyrosine Kinase Inhibitors or Venetoclax
19天前
已关闭
EPR26-165: Risk Factors for Infection in Chronic Lymphocytic Leukemia: Insights From a Real-World Cohort Treated With Bruton Tyrosine Kinase Inhibitors or Venetoclax
25天前
已关闭
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies
25天前
已完结
CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab
1个月前
已关闭
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025
1个月前
已完结
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications
1个月前
已完结
BCL ‐2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma
1个月前
已完结
SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma
3个月前
已完结
Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma
3个月前
已完结
Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review
3个月前
已完结
皖公网安备34019202002308
